earnings
confidence high
sentiment neutral
materiality 0.85
Bristol-Myers Q1 revenue $11.6B (+5%); Non-GAAP EPS $1.96 (+13%)
BRISTOL MYERS SQUIBB CO
2022-Q1 EPS reported
$0.59
revenue$11,648,000,000
- Revenue $11.648B, +5% YoY (7% ex FX); U.S. revenue $7.7B (+10%).
- GAAP EPS $0.59 (down 34%); Non-GAAP EPS $1.96 (up 13%); net $(0.10) Acquired IPRD impact.
- In-line products +8% (Eliquis $3.2B +11%, Opdivo $1.9B +12%).
- Revlimid $2.8B (-5%) and Abraxane $214M (-32%) as LOE pressures continue.
- FDA approved Opdualag (melanoma) and Camzyos (cardiomyopathy) in Q1.